HPHenna Pehkonen

Henna Pehkonen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Henna Pehkonen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biological evaluation of a glucose‐based boron carrier as a potential agent for boron neutron capture therapy

    by Surachet Imlimthan, Katayun Bahrami, Henna Pehkonen, Alessia Centanni, Ahmed B. Montaser, Arina Värä, Jelena Matović, Heidi Liljenbäck, Tatsiana Auchynnikava, Kristiina M. Huttunen, et al.

    Boron neutron capture therapy (BNCT) is an innovative radiation oncology approach that targets tumors selectively, minimizing damage to healthy tissues through high‐linear‐energy‐transfer particles released during the boron neutron capture reaction. Current boron carriers like sodium mercaptoundecahydrododecaborate (BSH) and L‐p‐boronophenylalanine (BPA) face limitations in specificity and solubility. Our recently developed 6‐O‐(o‐carboranylmethyl)‐d‐glucopyranose (B‐Glc) shows promise as an alternative, demonstrating strong interactions with glucose transporters in human head and neck squamous cell carcinoma (HNSCC) CAL 27 cells in vitro. This study aims to extend in vitro investigations to three additional patient‐derived human HNSCC cell lines (UT‐SCC‐14, UT‐SCC‐28, and UT‐SCC‐42B) and to further evaluate in vivo pharmacokinetics in selected HNSCC tumor xenografts. The B‐Glc showed superior uptake and favorable kinetic parameters compared to BPA and BSH in all tested cell lines. Initial positron emission tomography imaging using [18F]fluoro‐2‐deoxy‐d‐glucose ([18F]FDG) radiotracer confirmed increased glucose uptake in CAL 27 and UT‐SCC‐14 tumors in vivo, supported by glucose transporter 1 (GLUT1) expression observed in tumor section immunohistochemistry. Biodistribution studies of the B‐Glc (75 mg/kg dose) revealed no significant impact of blood glucose levels on tumor uptake, with peak boron accumulation at 15–30 min post‐injection, comparable uptake to the clinical BPA‐fructose complex (400 mg/kg dose) performance at 60 min, achieving the required tumor boron concentration (>20 ppm) for effective BNCT. Overall, this study underscores an advancement in targeted BNCT, highlighting B‐Glc as an effective GLUT1‐targeting carrier for enhanced therapeutic outcome in HNSCC and the potential to use [18F]FDG as a companion diagnostic for the glucoconjugate.


  • Open Access

    Liprin‐α1 contributes to oncogenic MAPK signaling by counteracting ERK activity

    by Henna Pehkonen, Artemis Filippou, Juho Väänänen, Iida Lindfors, Mira Vänttinen, Philipp Ianevski, Anne Mäkelä, Pauliina Munne, Juha Klefström, Sanna Toppila‐Salmi, et al.

    PTPRF interacting protein alpha 1 (PPFIA1) encodes for liprin-alpha 1, a member of the leukocyte common antigen-related protein tyrosine phosphatase (LAR-RPTPs)-interacting protein family. Liprin-alpha 1 localizes to adhesive and invasive structures in the periphery of cancer cells, where it modulates migration and invasion in head and neck squamous cell carcinoma (HNSCC) and breast cancer. To study the possible role of liprin-alpha 1 in anticancer drug responses, we screened a library of oncology compounds in cell lines with high endogenous PPFIA1 expression. The compounds with the highest differential responses between high PPFIA1-expressing and silenced cells across cell lines were inhibitors targeting mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinases (ERK) signaling. KRAS proto-oncogene, GTPase (KRAS)-mutated MDA-MB-231 cells were more resistant to trametinib upon PPFIA1 knockdown compared with control cells. In contrast, liprin-alpha 1-depleted HNSCC cells with low RAS activity showed a context-dependent response to MEK/ERK inhibitors. Importantly, we showed that liprin-alpha 1 depletion leads to increased p-ERK1/2 levels in all our studied cell lines independent of KRAS mutational status, suggesting a role of liprin-alpha 1 in the regulation of MAPK oncogenic signaling. Furthermore, liprin-alpha 1 depletion led to more pronounced redistribution of RAS proteins to the cell membrane. Our data suggest that liprin-alpha 1 is an important contributor to oncogenic RAS/MAPK signaling, and the status of liprin-alpha 1 may assist in predicting drug responses in cancer cells in a context-dependent manner.


  • Open Access

    Liprin-α1 Expression in Tumor-Infiltrating Lymphocytes Associates with Improved Survival in Patients with HPV-Positive Oropharyngeal Squamous Cell Carcinoma

    by Anni Sjöblom, Henna Pehkonen, Lauri Jouhi, Outi Monni, Reija Randén-Brady, Piia-Riitta Karhemo, Jussi Tarkkanen, Caj Haglund, Petri Mattila, Antti Mäkitie, et al.

    Background: Liprin-α1 is a scaffold protein involved in cell adhesion, motility, and invasion in malignancies. Liprin-α1 inhibits the expression of metastatic suppressor CD82 in cancers such as oral carcinoma, and the expression of these proteins has been known to correlate negatively. The role of these proteins has not been previously studied in human papillomavirus (HPV)-related head and neck cancers. Our aim was to assess the clinical and prognostic role of liprin-α1 and CD82 in HPV-positive oropharyngeal squamous cell carcinoma (OPSCC) in comparison to HPV-negative OPSCC. Methods: The data included 139 OPSCC patients treated at the Helsinki University Hospital (HUS) during 2012–2016. Immunohistochemistry was utilized in HPV determination and in biomarker assays. Overall survival (OS) was used in the survival analysis. Results: Stronger expression of liprin-α1 in tumor-infiltrating lymphocytes (TILs) was linked to lower cancer stage (p < 0.001) and HPV positivity (p < 0.001). Additionally, we found an association between elevated expression of liprin-α1 and weak expression of CD82 in tumor cells (p = 0.029). In survival analysis, we found significant correlation between favorable OS and stronger expression of liprin-α1 in TILs among the whole patient cohort (p < 0.001) and among HPV-positive patients (p = 0.042). Conclusions: Increased liprin-α1 expression in the TILs is associated with favorable prognosis in OPSCC, especially among HPV-positive patients.

  • Open Access

    Liprins in oncogenic signaling and cancer cell adhesion

    by Henna Pehkonen, Ivan de Curtis, Outi Monni

    Liprins are a multifunctional family of scaffold proteins, identified by their involvement in several important neuronal functions related to signaling and organization of synaptic structures. More recently, the knowledge on the liprin family has expanded from neuronal functions to processes relevant to cancer progression, including cell adhesion, cell motility, cancer cell invasion, and signaling. These proteins consist of regions, which by prediction are intrinsically disordered, and may be involved in the assembly of supramolecular structures relevant for their functions. This review summarizes the current understanding of the functions of liprins in different cellular processes, with special emphasis on liprins in tumor progression. The available data indicate that liprins may be potential biomarkers for cancer progression and may have therapeutic importance.


  • Open Access

    ANO1 Expression Orchestrates p27Kip1/MCL1-Mediated Signaling in Head and Neck Squamous Cell Carcinoma

    by Artemis Filippou, Henna Pehkonen, Piia-Riitta Karhemo, Juho Väänänen, Anni I. Nieminen, Juha Klefström, Reidar Grénman, Antti A. Mäkitie, Heikki Joensuu, Outi Monni

    Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous group of tumors that derive from the mucosal epithelium of the upper aerodigestive tract and present high mortality rate. Lack of efficient targeted-therapies and biomarkers towards patients’ stratification are caveats in the disease treatment. Anoctamin 1 (ANO1) gene is amplified in 30% of HNSCC cases. Evidence suggests involvement of ANO1 in proliferation, migration, and evasion of apoptosis; however, the exact mechanisms remain elusive. Aim of this study was to unravel the ANO1-dependent transcriptional programs and expand the existing knowledge of ANO1 contribution to oncogenesis and drug response in HNSCC. We cultured two HNSCC cell lines established from primary tumors harboring amplification and high expression of ANO1 in three-dimensional collagen. Differential expression analysis of ANO1-depleted HNSCC cells demonstrated downregulation of MCL1 and simultaneous upregulation of p27Kip1 expression. Suppressing ANO1 expression led to redistribution of p27Kip1 from the cytoplasm to the nucleus and associated with a cell cycle arrested phenotype. ANO1 silencing or pharmacological inhibition resulted in reduction of cell viability and ANO1 protein levels, as well as suppression of pro-survival BCL2 family proteins. Collectively, these data provide insights of ANO1 involvement in HNSCC carcinogenesis and support the rationale that ANO1 is an actionable drug target.